• Earlier this month, Reinsurance Group of America announced the opening of its first New York City office at Park Avenue Tower, reflecting a focus on high-quality assets and a people-first workplace in a premier Midtown Manhattan location.
• On the research front, RGA's recent study suggests that widespread adoption of GLP-1 medications could lower US mortality by 3.5% by 2045, underscoring potential long-term implications for population health and the insurance sector.
• We will examine how the projected mortality benefits from GLP-1 drugs could influence RGA's risk outlook and earnings potential.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Reinsurance Group of America Investment Narrative Recap

To be a shareholder in Reinsurance Group of America, you need to believe in the company's ability to manage complex insurance risks while growing through its diverse, international portfolio and maintaining financial flexibility. The recent opening of RGA’s New York City office signals a commitment to premium assets and operational strength, but does not materially impact the short-term focus on stabilizing earnings amid claims volatility or address ongoing margin pressures from rising healthcare costs, the biggest current risks to the business model. Among recent company updates, RGA’s completion of share repurchases totaling US$75 million in Q3 2025 supports the catalyst of capital return and may reinforce investor confidence, especially as the company benefits from improved net margins and robust earnings growth. This buyback initiative complements the improved value creation profile but does not mitigate concerns tied to sector-specific medical cost trends or earnings variability. In contrast, what investors should not ignore is how persistent volatility in US individual life claims may affect RGA's...

Reinsurance Group of America's narrative projects $29.2 billion in revenue and $1.9 billion in earnings by 2028. This requires 10.3% yearly revenue growth and a $1.13 billion increase in earnings from the current $770 million.

Uncover how Reinsurance Group of America's forecasts yield a $236.89 fair value, a 26% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have issued fair value estimates ranging from US$195 to US$613 for RGA, reflecting three unique viewpoints. While opinions widely differ, the ongoing variability in healthcare claims costs remains a key issue for future earnings stability.

Explore 3 other fair value estimates on Reinsurance Group of America - why the stock might be worth just $195.00!

Build Your Own Reinsurance Group of America Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Reinsurance Group of America research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Reinsurance Group of America research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Reinsurance Group of America's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.